Blueprint Medicines (BPMC) Competitors

BioNTech (NASDAQ:BNTX) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment, dividends and community ranking.

Which has more volatility and risk, BNTX or BPMC?

BioNTech has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Which has stronger valuation & earnings, BNTX or BPMC?

BioNTech has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.75B	8.90	$1.01B	-$3.40	-29.92
Blueprint Medicines	$562.12M	11.83	-$67.09M	-$2.47	-41.70

Is BNTX or BPMC more profitable?

Blueprint Medicines has a net margin of -13.19% compared to BioNTech's net margin of -15.16%. BioNTech's return on equity of -2.35% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-15.16%	-2.35%	-2.05%
Blueprint Medicines	-13.19%	-77.49%	-20.84%

Does the MarketBeat Community believe in BNTX or BPMC?

Blueprint Medicines received 406 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 68.23% of users gave Blueprint Medicines an outperform vote while only 47.44% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
BioNTech	Outperform Votes 148 47.44%	Underperform Votes 164 52.56%
Blueprint Medicines	Outperform Votes 554 68.23%	Underperform Votes 258 31.77%

Does the media refer more to BNTX or BPMC?

In the previous week, BioNTech had 3 more articles in the media than Blueprint Medicines. MarketBeat recorded 19 mentions for BioNTech and 16 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 1.49 beat BioNTech's score of 1.19 indicating that Blueprint Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	9 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Blueprint Medicines	15 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals have more ownership in BNTX or BPMC?

15.5% of BioNTech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Do analysts recommend BNTX or BPMC?

BioNTech presently has a consensus price target of $142.08, indicating a potential upside of 39.68%. Blueprint Medicines has a consensus price target of $126.56, indicating a potential upside of 22.88%. Given BioNTech's stronger consensus rating and higher possible upside, equities analysts clearly believe BioNTech is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.89
Blueprint Medicines	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

BioNTech beats Blueprint Medicines on 12 of the 18 factors compared between the two stocks.